Cargando…
Myostatin in idiopathic inflammatory myopathies: Serum assessment and disease activity
AIMS: In idiopathic inflammatory myopathies (IIM), disease activity is difficult to assess, and IIM may induce severe muscle damage, especially in immune‐mediated necrotising myopathies (IMNM) and inclusion body myositis (IBM). We hypothesise that myostatin, a negative regulator of muscle mass, coul...
Autores principales: | Mahoudeau, Alexandrine, Anquetil, Céline, Tawara, Nozomu, Khademian, Hossein, Amelin, Damien, Bolko, Loïs, Silvestro, Marco, Cin, Julian Dal, Tendrel, Bérénice, Tardif, Virginie, Mariampillai, Kubéraka, Butler‐Browne, Gillian, Benveniste, Olivier, Allenbach, Yves |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10092350/ https://www.ncbi.nlm.nih.gov/pubmed/36168256 http://dx.doi.org/10.1111/nan.12849 |
Ejemplares similares
-
The role of interferons type I, II and III in myositis: A review
por: Bolko, Loïs, et al.
Publicado: (2021) -
MRI and muscle imaging for idiopathic inflammatory myopathies
por: Malartre, Samuel, et al.
Publicado: (2021) -
Efficacy of Rituximab in Refractory Inflammatory Myopathies Associated with Anti- Synthetase Auto-Antibodies: An Open-Label, Phase II Trial
por: Allenbach, Yves, et al.
Publicado: (2015) -
Pulmonary arterial hypertension in idiopathic inflammatory myopathies: Data from the French pulmonary hypertension registry and review of the literature
por: Sanges, Sébastien, et al.
Publicado: (2016) -
Long-term exposure to Myozyme results in a decrease of anti-drug antibodies in late-onset Pompe disease patients
por: Masat, Elisa, et al.
Publicado: (2016)